Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

MLA

Gigante, Elia, et al. “Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.” Liver Cancer (2235-1795), vol. 11, no. 5, Sept. 2022, pp. 460–73. EBSCOhost, https://doi.org/10.1159/000525488.

APA

Gigante, E., Hobeika, C., Le Bail, B., Paradis, V., Tougeron, D., Lequoy, M., Bouattour, M., Blanc, J.-F., Ganne-Carrié, N., Tran, H., Hollande, C., Allaire, M., Amaddeo, G., Regnault, H., Vigneron, P., Ronot, M., Elkrief, L., Verset, G., Trepo, E., & Zaanan, A. (2022). Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. Liver Cancer (2235-1795), 11(5), 460–473. https://doi.org/10.1159/000525488

Chicago

Gigante, Elia, Christian Hobeika, Brigitte Le Bail, Valérie Paradis, David Tougeron, Marie Lequoy, Mohamed Bouattour, et al. 2022. “Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.” Liver Cancer (2235-1795) 11 (5): 460–73. doi:10.1159/000525488.